TCMBANKIN000018 |
aloperine |
|
C15H24N2 |
232.36 g/mol |
C1CCN2CC3CC(C2C1)C=C4C3NCCC4 |
TCMBANKIN000095 |
oxymatrine |
Ammothamnine; STOCK1N-33797 |
C15H24N2O2 |
264.36 |
C1CC2C3CCC[N+]4(C3C(CCC4)CN2C(=O)C1)[O-] |
TCMBANKIN001842 |
indolyl-3-carbaldehyde |
|
|
|
|
TCMBANKIN003167 |
oxytocin |
|
C43H66N12O12S2 |
1007.2 g/mol |
CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N |
TCMBANKIN013879 |
3'-methoxyluteolin |
|
|
|
|
TCMBANKIN015172 |
Matsukaze lactone |
MLS002472930; 7-methoxy-8-(7-methoxy-2-oxo-6-chromenyl)-2-chromenone; CHEMBL1877565; matsukazelactone; 7-methoxy-8-(7-methoxy-2-oxochromen-6-yl)chromen-2-one; 7-methoxy-8-(7-methoxy-2-oxo-chromen-6-yl)chromen-2-one; matsukaze lactone; SMR001397040; 8-(2-keto-7-methoxy-chromen-6-yl)-7-methoxy-coumarin; AC1NSXWA; HMS2268O14 |
C20H14O6 |
350.3 g/mol |
COC1=C(C2=C(C=C1)C=CC(=O)O2)C3=C(C=C4C(=C3)C=CC(=O)O4)OC |
TCMBANKIN027512 |
matrine |
.alpha.-Matrine; Matrene, (+)-; STOCK1N-36535; Matrine; BRN 0085851; (+)-Matrine; ZINC4196454; 519-02-8; Matridin-15-one (9CI); C10774; NSC146051; 5-24-02-00301 (Beilstein Handbook Reference); NSC 146051 |
C15H24N2O |
248.36 |
C1CC2C3CCCN4C3C(CCC4)CN2C(=O)C1 |
TCMBANKIN029350 |
Sophoramine |
MMCQRJPAMIHLQX-UHFFFAOYSA-N; Matridin-15-one, 11,12,13,14-tetradehydro-, (6.beta.)-; 1H,5H,10H-Dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one, 2,3,6,7,7a,8,13b,13c-octahydro-, (7aS,13bS,13cR)-; C10782; 1H,5H,10H-Dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one, 2,3,6,7,7a,8,13b,13c-octahydro-, [7aS-(7a.alpha.,13b.alpha.,13c.beta.)]-; sophoramine; 11,12,13,14-Tetradehydromatridin-15-one-, (6.beta.)-; AC1LDGYG; 6-Isosophoramine; STOCK1N-57738; Isosophoramine; Matridin-15-one, 11,12,13,14-tetradehydro-; 6882-66-2 |
C15H20N2O |
244.33 |
C1CC2CN3C(=O)C=CC=C3C4C2N(C1)CCC4 |
TCMBANKIN032971 |
5,6-dihydroxy-3,7-dimethoxy-2-(4-methoxyphenyl)chromone |
5,6-dihydroxy-3,7-dimethoxy-2-(4-methoxyphenyl)-4-chromenone; 5,6-dihydroxy-3,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one |
|
344.34 |
|
TCMBANKIN036810 |
Butein |
1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 2′,4′,3,4-Tetrahydroxychalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-, (2E)-; NCGC00163519-01; (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; NSC652892; AIDS057944; AC1NST6X; AIDS-057944; 3,4,2',4'-Tetrahydroxychalcone; ST5331397; 2',3,4,4'-Tetrahydrochalcone; 2',3,4,4'-Tetrahydroxychalcone; B178_SIGMA; butein ; MolMap_000005; Chalcone, 2',3,4,4'-tetrahydroxy- (7CI,8CI); EINECS 207-659-5; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-; C08578; butein; 2',4',3,4-Tetrahydroxychalcone; 2′,3,4,4′-Tetrahydroxychalcone; Acrylophenone, 2',4'-dihydroxy-3-(3,4-dihydroxyphenyl)-; NCI60_018489; HSCI1_000162; 21849-70-7; (Z)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 487-52-5; 1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one |
C15H12O5 |
272.25 |
C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O |
TCMBANKIN036859 |
Sophoridine |
.alpha.-Matrine; FT-0696735; MLS000029265; FT-0603438; HMS2269A14; NSC-143088; SR-01000601144-3; HMS1611N16; NSC-318810; Sophoridin; SMR000011610; FT-0628171; (5-beta)-Matridin-15-one; Oprea1_860679; Oprea1_680866; Matridin-15-one, (5-beta)- (9CI); BAS 02913238; Matrene, (+)-; NEW BASE STRUCTURE; MolPort-001-985-870; 6.beta.,7.beta.-Matrine; 2,3,5,6,6a,10,11,11a,11b,11c-Decahydro-4H,7H-3a,7a-diaza-1H-benzo[de]anthracene-8(9H)-one; Matridin-15-one; Dihydro-5-episophocarpine; SR-01000601144; SCHEMBL8260145; NSC318810; dodecahydro-1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one; W-3063; CHEMBL1733145; regid845916; ZX-AN036540; 83148-91-8; MFCD02735434; AC1L63MI; AB00397099-11; 1H,5H,10H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one, dodecahydro-; AKOS017259293; ALBB-020900; AKOS000591194; NSC143088; MCULE-1489142812; Q-100583; BB_NC-1021; 5-Epidihydrosophocarpine; ZSBXGIUJOOQZMP-UHFFFAOYSA-N; 6882-68-4; (+)-Matrine; Sophoridine; SC-25809; l-Sophoridine; Dodecahydro-3a,7a-diaza-benzo[de]anthracen-8-one; 4CN-1610 |
|
248.364 |
|
TCMBANKIN039828 |
sophoranochromene |
LMPK12140052; Sophoranochromene |
C30H34O4 |
458.6 g/mol |
CC(=CCC1=CC(=CC2=C1OC(C=C2)(C)C)C3CC(=O)C4=C(O3)C(=C(C=C4)O)CC=C(C)C)C |
TCMBANKIN041550 |
N-Oxysophocarpine |
N1280; AC-7981; SCHEMBL15133349; 26904-64-3; N-Oxysophocarpine; n-oxysophocarpine; AKOS015965398; 2,3,6,7,7a,8,13,13a,13b,13c-Decahydro-1H,5H,10H-dipyrido[2,1-f:3,2,1-ij][1,6]naphthyridin-10-one 4-oxide #; QMGGMESMCJCABO-UHFFFAOYSA-N; Oxysophocarpine; Sophocarpine, N-oxide; 6-OXO-7,13-DIAZATETRACYCLO[7.7.1.0(2),?.0(1)(3),(1)?]HEPTADEC-4-EN-13-IUM-13-OLATE; AC1LDHOM; FT-0689395 |
|
262.35 |
|
TCMBANKIN045310 |
Daechualkaloid A |
2,4,5,6-tetrahydro-1H-cyclopenta[d][1,3]oxazin-7-one; daechualkaloid a; AC1NSU54; daechu alkaloid a |
C10H13NO2 |
179.22 g/mol |
C1CC2N(C1)C3=C(CCC3=O)CO2 |
TCMBANKIN048523 |
Cytisine |
PDSP2_000459; SCHEMBL13595657; cytisine; HMS1569N10; SPBio_002807; Prestwick0_000624; (1S,5R)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one; Prestwick2_000624; C10763; Prestwick1_000624; STK080772; 485-35-8 |
C11H14N2O |
190.24 |
C1C2CNCC1C3=CC=CC(=O)N3C2 |
TCMBANKIN058113 |
Butein |
1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 2′,4′,3,4-Tetrahydroxychalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-, (2E)-; NCGC00163519-01; (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; NSC652892; AIDS057944; AC1NST6X; AIDS-057944; 3,4,2',4'-Tetrahydroxychalcone; ST5331397; 2',3,4,4'-Tetrahydrochalcone; 2',3,4,4'-Tetrahydroxychalcone; B178_SIGMA; butein ; MolMap_000005; Chalcone, 2',3,4,4'-tetrahydroxy- (7CI,8CI); EINECS 207-659-5; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-; C08578; butein; 2',4',3,4-Tetrahydroxychalcone; 2′,3,4,4′-Tetrahydroxychalcone; Acrylophenone, 2',4'-dihydroxy-3-(3,4-dihydroxyphenyl)-; NCI60_018489; HSCI1_000162; 21849-70-7; (Z)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; 487-52-5; 1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one |
C15H12O5 |
272.25 |
C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O |
TCMBANKIN058559 |
sophojaponicin |
(+)-Maackiain 3-O-glucoside; LMPK12070032; Sophojaponicin; sophoraponicin |
C22H22O10 |
446.4 |
C1C2C(C3=C(O1)C=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O)OC5=CC6=C(C=C25)OCO6 |
TCMBANKIN058600 |
lehmannine |
Matridin-15-one, 12,13-didehydro-; 12,13-Didehydromatridin-15-one; BRN 0885357; 12-Dehydromatrine; 58480-54-9; (+)-lehmannine; Lehmanine |
C15H22N2O |
246.35 g/mol |
C1CC2CN3C(C=CCC3=O)C4C2N(C1)CCC4 |
TCMBANKIN058601 |
oxysophocarpine |
N1280; AC-7981; SCHEMBL15133349; 26904-64-3; N-Oxysophocarpine; n-oxysophocarpine; AKOS015965398; 2,3,6,7,7a,8,13,13a,13b,13c-Decahydro-1H,5H,10H-dipyrido[2,1-f:3,2,1-ij][1,6]naphthyridin-10-one 4-oxide #; QMGGMESMCJCABO-UHFFFAOYSA-N; Oxysophocarpine; Sophocarpine, N-oxide; 6-OXO-7,13-DIAZATETRACYCLO[7.7.1.0(2),?.0(1)(3),(1)?]HEPTADEC-4-EN-13-IUM-13-OLATE; AC1LDHOM; FT-0689395; sophocarpine n-oxide; N-oxysophocarpine; OXYSOPHOCARPINE |
C15H22N2O2 |
262.35 g/mol |
C1CC2CN3C(CC=CC3=O)C4C2[N+](C1)(CCC4)[O-] |
TCMBANKIN058602 |
(?)-9α-hydroxylsophocarpine |
(-)-9alpha-hydroxysophoramine; (- )-9α-hydroxysophocarpine; (- )-9α-hydroxysophoramine |
C15H22N2O2 |
262.39 |
C1CC2CN3C(CC=CC3=O)C4C2N(C1)CC(C4)O |
TCMBANKIN058603 |
sophocarpine |
Sophocarpine; ZINC5282946; AIDS-122681; AIDS122681; 145572-44-7 (MONOHYDRATE); (-)-(7aS,13aR,13bR,13cS)-2,3,6,7,7a,8,13,13a,13b,13c-Decahydro-1H,5H,10H-dipyrido[2,1-f:3,2,1-ij][1,6]naphthyridin-10-one; Matridin-15-one, 13,14-didehydro-; Matridin-15-one, 13,14-didehydro- (9CI); (-)-Sophocarpine; 1H,5H,10H-Dipyrido(2,1-f:3',2',1'-ij)(1,6)naphthyridin-10-one, 2,3,6,7,7a,8,13,13a,13b,13c-decahydro-, (7aS,13aR,13bR,13cS)-; BB_NC-1020; 13,14-Didehydromatridin-15-one; (-)-sophocarpine |
C15H22N2O |
246.35 g/mol |
C1CC2CN3C(CC=CC3=O)C4C2N(C1)CCC4 |
TCMBANKIN060693 |
Sitogluside |
|
C35H60O6 |
576.85g/mol |
CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC5C(C(C(C(O5)CO)O)O)O)C)C)C(C)C |
TCMBANKIN061311 |
N-methylcytisine |
|
C12H16N2O |
204.27 |
CN1CC2CC(C1)C3=CC=CC(=O)N3C2 |
TCMBANKIN061371 |
nicotine |
36733_RIEDEL; 2yk1; CHEBI:59806; 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine; (2S)-1-methyl-2-(pyridin-3-yl)pyrrolidinium; (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE; D03365; 54-11-5; NCGC00090693-03; 46343_RIEDEL; C00745; Nicotine; NCGC00090693-04; AIDS-156031; 65-31-6 (R,R-BITARTRATE); (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine; (S)-3-(N-methylpyrrolidin-2-yl)pyridine; Habitrol (TN); SBB012359; N5511_SIGMA; (−)-Nicotine; Nicotine (compounds related to); PDSP2_000555; NCT; N3876_SIGMA; 3-[(2S)-1-methyl-2-pyrrolidinyl]pyridine; NCGC00090693-01; ZB012057; (S)-(-)-nicotine; CHEBI:17688; SDCCGMLS-0066911.P001; (S)-nicotinium(1+); AC1OCG5J; 3-(2-(N-methylpyrrolidinyl))pyridine; NSC97238 (R,R-BITARTRATE SALT); 3-[(2S)-1-methylpyrrolidin-1-ium-2-yl]pyridine; (S)-nicotinium cation; AIDS156031; NCGC00090693-05; PDSP1_000465; PDSP1_000113; PDSP2_000463; (S)-3-(1-methylpyrrolidin-2-yl)pyridine; Nicotine (USP); 54-11-5 (FREE BASE); L(-)-nicotine; (−)-Nicotine solution |
C10H14N2 |
162.23 g/mol |
CN1CCCC1C2=CN=CC=C2 |
TCMBANKIN061386 |
Oxynarcotine |
2,3-dimethoxy-6-(2-{4-methoxy-6-[2-(methylamino)ethyl]-2H-1,3-benzodioxol-5-yl}acetyl)benzoic acid; AC1NSZCW; SCHEMBL11790808; 2,3-dimethoxy-6-[2-[4-methoxy-6-(2-methylaminoethyl)-1,3-benzodioxol-5-yl]-1-oxoethyl]benzoic acid; 2,3-dimethoxy-6-[2-[4-methoxy-6-(2-methylaminoethyl)-1,3-benzodioxol-5-yl]acetyl]benzoic acid; 2,3-dimethoxy-6-[2-[4-methoxy-6-(2-methylaminoethyl)-1,3-benzodioxol-5-yl]ethanoyl]benzoic acid; Nornarceine; 2,3-dimethoxy-6-[2-[4-methoxy-6-[2-(methylamino)ethyl]-1,3-benzodioxol-5-yl]acetyl]benzoic acid; oxynarcotine; nornarceine |
C22H25NO8 |
431.44 g/mol |
CNCCC1=CC2=C(C(=C1CC(=O)C3=C(C(=C(C=C3)OC)OC)C(=O)O)OC)OCO2 |